Kyrsten Sinema actually said...

Proxy advisory firms' outsized influence on emerging companies can be uniquely damaging to small, growing biotechs.

I am encouraged that the subcommittee is holding today's hearing to examine the impact of such roadblocks on smaller public companies.

In an effort to ensure that costly regulations don't stand in the way of success for biopharma and other companies on the cutting edge of sc...

We must have up to date information and a coordinated strategy to disrupt its funding sources.